Seeking Alpha

Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis

Results suggest real-world effectiveness of neffy is consistent with that historically reported for epinephrine injection Figure 1: Treatment success rate with a single dose of neffy administered by a ...
Nasdaq

neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)

neffy is the first epinephrine product approved for use out of a hospital setting in China for adults and children (>30 kg) living with severe allergic reactions Pediatrix Therapeutics, which has a ...
Healio

Q&A: Company seeks to expand neffy FDA approval to more pediatric patients

Please provide your email address to receive an email when new articles are posted on . Children as young as age 10 years are able to self-administer neffy 1 mg. ARS Pharmaceuticals is also working on ...
Seeking Alpha

California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from ...
Nasdaq

ARS Pharmaceuticals Expands neffy Access to 30 Formularies, Improving Coverage for Type 1 Allergy Patients

ARS Pharmaceuticals, Inc. has announced the addition of neffy® (epinephrine nasal spray) to the formularies of Cigna Healthcare, Navitus Health Systems, and OptumRx, expanding access to approximately ...
Healio

ARS Pharma to provide free neffy epinephrine nasal spray to schools

Please provide your email address to receive an email when new articles are posted on . 4 million children in the United States have a food allergy. The neffyinSchools program provides four free doses ...